On November 22, 2023, Vivodyne, a biotech start-up that discovers and develops more effective drugs by testing them on lab-grown human organs, announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures. Wilson Sonsini Goodrich & Rosati advised Khosla Ventures on patent strategy matters related to the financing.

The funding will advance Vivodyne’s discovery pipeline and clinically predictive AI stack, which identifies novel therapeutic targets and predicts patient responses to new drugs by testing directly on lab-grown human organ tissues. Vivodyne has bioengineered over 20 types of human organ tissues that mimic native human physiology and function to accurately capture the effects of new therapies and predict patient outcomes at the cellular, tissue, organ, and systemic scale.

The Wilson Sonsini team that advised Khosla Ventures on patent strategy matters included Matthew Bresnahan, Alicia Umpierre, , and Scott May.

For more information, please see Vivodyne’s press release.